Cholesterol: What LDL Actually Does, Why 'Good' and 'Bad' Is an Oversimplification, and How to Reduce It

Cholesterol is the molecule that made nutritional epidemiology internationally famous in the 1950s by being the wrong explanation for the right observation. Ancel Keys noted that saturated fat intake correlated with cardiovascular mortality across countries. He attributed this to dietary cholesterol increasing serum cholesterol increasing cardiovascular disease. The first step of that chain was wrong — dietary cholesterol changes serum cholesterol modestly in most people. The other two relationships are real.

The simplified narrative ("cholesterol bad, reduce cholesterol intake") became dietary orthodoxy for decades, was wrong in important ways, and the updated model is more useful.

What Cholesterol Is

Cholesterol is a lipid molecule that serves as:

• A structural component of all cell membranes (maintains fluidity and integrity)
• A precursor for steroid hormones (testosterone, estrogen, cortisol, aldosterone)
• A precursor for vitamin D synthesis
• A component of bile acids (required for fat digestion)

The liver synthesizes approximately 75–80% of total body cholesterol. Dietary intake provides approximately 20–25%. The liver downstream-regulates its synthesis when dietary intake increases — which is why dietary cholesterol has a smaller effect on serum cholesterol than was historically assumed.

The LDL Particle Problem

Cholesterol does not travel through the bloodstream freely — it is packaged in lipoprotein particles. LDL (low-density lipoprotein) carries cholesterol from the liver to peripheral tissues. VLDL carries triglycerides from liver. HDL collects cholesterol from peripheral tissues back to the liver.

The atherogenic mechanism: LDL particles enter the intima of arterial walls, particularly where endothelial shear stress is irregular (arterial branch points). Once in the intima, LDL particles undergo oxidation, triggering an inflammatory response — macrophages engulf the oxidized LDL, becoming foam cells, which aggregate into fatty streaks, which become atheromatous plaques.

The key variable for atherosclerosis risk is not LDL-C (how much cholesterol per particle) but ApoB — the number of atherogenic particles, each of which is capable of initiating the plaque sequence. A higher particle number means more opportunities for intimal penetration.

> 📌 Sniderman et al. (2019) reviewing the superiority of ApoB over LDL-C as a cardiovascular risk marker found that approximately 30–40% of patients with normal LDL-C have elevated ApoB (more particles than expected for the cholesterol content), producing a risk misclassification when only LDL-C is measured. [1]

How to Reduce Atherogenic Risk

ApoB/LDL particle reduction:

• Replace saturated fat with unsaturated fat (particularly polyunsaturated): reduces LDL-C and LDL particle number
• Increase soluble fiber intake (oats, legumes, psyllium): soluble fiber binds bile acids in the gut, increasing hepatic bile acid synthesis and reducing hepatic cholesterol availability
• Reduce refined carbohydrates and added sugar: reduces VLDL and small dense LDL (the more atherogenic LDL subtype)
• Physical activity: reduces triglycerides, increases HDL

Statins: The primary pharmaceutical intervention. HMG-CoA reductase inhibitors reduce hepatic cholesterol synthesis, reducing LDL-C and LDL particle number reliably. Effects: approximately 40–50% LDL-C reduction at standard doses.

The "cholesterol is not the problem" narrative from some alternative health sources: Correct that dietary cholesterol is not the primary driver. Incorrect when used to dismiss LDL-C and ApoB as risk factors — the particle penetration mechanism is among the most replicated findings in cardiovascular biology.

---

Key Terms

• ApoB (Apolipoprotein B) — the protein coat of every atherogenic lipoprotein particle; each particle carries exactly one ApoB; ApoB count equals atherogenic particle count; more predictive of cardiovascular risk than LDL-C
• LDL particle number vs. LDL-C — the distinction between counting particles (ApoB) and measuring cholesterol content per particle (LDL-C); concordant in most people at average cholesterol concentrations; discordant in those with small, dense LDL or low cholesterol per particle
• Endothelial shear stress — the mechanical force of blood flow on arterial wall cells; irregular at branch points and curves; the preferred location for LDL particle infiltration and plaque initiation
• HMG-CoA reductase — the rate-limiting enzyme in hepatic cholesterol synthesis; the target of statin drugs; inhibition reduces endogenous cholesterol production and upregulates LDL receptor expression, clearing LDL from circulation

---

Scientific Sources

• 1. Sniderman, A.D., et al. (2019). Apolipoprotein B particles and cardiovascular disease: A narrative review. JAMA Cardiology, 4(12), 1287–1295. PubMed
• 2. Grundy, S.M., et al. (2018). 2018 AHA/ACC guideline on the management of blood cholesterol. Journal of the American College of Cardiology, 73(24), e285–e350. PubMed